the hospital without fever and with a 1-week history of leftside abdominal pain (table 1) . A nontender pulsatile mass was felt in the left side of the abdomen. Blood tests revealed a WBC count of 8900 cells/mm 3 (with a normal neutrophil count) and a hemoglobin level of 11.7 g/dL. CT of the abdomen showed an infrarenal abdominal aortic aneurysm (AAA), and the patient underwent repair of the AAA. After surgery, he developed new fever with wound discharge and leukocytosis of increasing severity. A second laparotomy revealed fluid in the pelvic cavity and pus around the para-aortic region. Cultures of blood and pus obtained from the peritoneal cavity and para-aortic area yielded B. pseudomallei, confirming the diagnosis of mycotic aneurysm. Patient 2 also developed septic arthritis in the left knee, and culture of an aspirate yielded B. pseudomallei with the same antibiogram as the previously isolated strain. He was treated with intravenous ceftazidime for 8 weeks and was discharged from the hospital receiving maintenance doxycyline therapy.
Four years later, patient 2 presented to the hospital with fever and abdominal pain while he was still receiving doxycycline. CT of the abdomen confirmed a loculated fluid collection around the upper abdominal aorta, with splenic microabscesses. The abdominal aortic graft was intact. Patient 2 underwent resection of the mycotic abdominal pseudoaneurysm, which involved removal of the infected graft, and ligation of the infrarenal abdominal aorta and both common iliac arteries with axillobifemoral bypass. Culture of tissue and blood clot specimens yielded B. pseudomallei and methicillinresistant Staphylococcus aureus. Patient 2 was treated with intravenous ceftazidime and vancomycin and oral trimethoprimsulfamethoxazole (TMP-SMZ) for 6 weeks and was prescribed lifelong oral doxycycline and TMP-SMZ therapy. Five years later, the patient's most recent follow-up examination revealed that he remained healthy.
Patient 6, a 60-year-old man with type 2 diabetes mellitus and hypertension, was admitted to the hospital with a 3-week history of fever, chills, and rigors. Examination revealed that he was febrile (temperature, 38.2ЊC), and hepatosplenomegaly was detected. Blood testing showed a WBC count of 16,400 cells/mm 3 (with 87.4% neutrophils) and a hemoglobin level of 11.8 g/dL. The patient was treated empirically with intravenous ceftriaxone and metronidazole. Fever persisted during the next 48 h, with new central abdominal pain; antibiotic therapy was switched to high-dose ceftazidime for possible melioidosis infection. CT of the abdomen revealed an infrarenal AAA. The patient underwent ligation and excision of the AAA with right axillobifemoral bypass. Cultures of tissue, pus, and blood specimens were positive for B. pseudomallei. The patient received 2 weeks of intravenous ceftazidime followed by 2 weeks of imipenem for treatment of central line-associated bacteremia.
Patient 6 was discharged receiving amoxicillin/clavulanate and doxycycline but was readmitted to the hospital 2 weeks later with complaints of blood-streaked stools. The hemoglobin level at readmission was 6.3 g/dL, and the WBC count was 9900 cells/mm 3 . Urgent esophagogastroduodenoscopy revealed a blood clot overlying the posterior wall of the third part of the duodenum. The patient was taken to the operating room for treatment of a suspected aortoenteric fistula. During surgery, multiple intra-abdominal abscesses were seen, with an aortoenteric fistula between the ligated stump and the posterior wall of the duodenojejunal flexure. Exploration of the aortic stump was followed by ligation of the aortoenteric fistula. The patient died later that night. Discussion. Aneurysms of the arterial system are rare, and mycotic aneurysms are even rarer in the era of antibiotics. Hematogenous seeding of a previously damaged arteriosclerotic vessel constitutes the most common mechanism of infection. The usual etiological agents implicated are S. aureus and nontyphoidal Salmonella species. Melioidosis is not even mentioned as a cause of mycotic aneurysms in infectious diseases references, such as Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases [7] . In the report by Currie et al. [8] , mycotic aneurysms only accounted for 1% of all deep infections, but the prevalence appears to be much higher among infected animals [9] .
A literature search revealed that 6 cases were reported during 1995-2003. Five of 6 patients were male, and the mean age was 62.3 years (table 2). All patients had a history of exposure to soil in an area in which melioidosis is endemic or had resided in a region of endemicity. The majority of these patients had no significant comorbidities, except for the Taiwanese patient, who had type 2 diabetes mellitus [6] . Fever was the only consistent clinical feature. Leukocyte counts ranged from 5660 to 27,300 leukocytes/mm 3 . Diagnoses of aneurysms were made on the basis of CT findings, and cultures of either blood, pus, or tissue specimens identified B. pseudomallei as the etiological agent. One patient did not receive appropriate antibiotics after surgical resection of the aneurysm and nephrectomy for hydronephrosis. He had relapse with a renal fossa abscess [1] . Patel et al. [4] did not mention whether their patient received maintenance therapy after an initial presentation of disseminated melioidosis with splenic abscesses, which necessitated a splenectomy when the patient subsequently relapsed with an aortoenteric fistula. The patient described by Luo et al. [6] had multiple relapses, despite receiving appropriate antibiotics. One patient died from a ruptured aneurysm, despite intravenous ceftazidime, without performance of surgical resection [2] .
In our series, all patients were men, with a mean age of 60 years. However, diabetes was a more consistent risk factor, with 2 patients presenting with undiagnosed diabetes. Only 1 patient, who was a gardener, had a significant history of soil exposure. Fever was not a consistent feature. The majority of our patients had chest or abdominal pain. Leukocyte counts ranged from 8410 to 19,000 leukocytes/mm 3 . CT established the diagnosis of aneurysm, which was most commonly located in the infrarenal aorta. B. pseudomallei was readily cultured from the infected sites and from blood. All patients underwent surgery and were treated for у4 weeks with intravenous antibiotics followed by maintenance oral therapy. Patients 2 and 4 were prescribed lifelong maintenance treatment after relapse with graft infections. Patient 6 died from an aortoenteric fistula despite appropriate interventions. Melioidosis has been known to be the presenting feature of diabetes, and diabetes mellitus is well documented to be a risk factor for bacteremic melioidosis [10] . Three of our patients had diabetes mellitus, which was discovered in 2 of them when they presented with melioidosis.
There is currently no standardized antimicrobial regimen or duration of treatment for melioidosis [11] . Response to treatment is often slow, and the disease is prone to relapse even after years of apparent quiescence [12, 13] . The antibiotic of choice for acutely septicemic patients is ceftazidime, which is superior to other third-generation cephalosporins or the combination of chloramphenicol, doxycycline, and TMP/SMZ [11, 14] . Ceftazidime therapy is equivalent to therapy with imipenem and intravenous amoxicillin/clavulanate with respect to mortality rate [14] , but a higher treatment failure rate is associated with intravenous amoxicillin-clavulanate [15] . Oral maintenance treatment with chloramphenicol, TMP-SMZ, and doxycycline appeared to reduce the risk of relapse to !5%, but adherence is poor, and the regimen is associated with a greater number of adverse effects [16] . Doxycycline monotherapy is inferior to combination therapy with chloramphenicol, TMP-SMZ, and doxycycline, with a relapse rate of 120% [17] . This is consistent with our experience. Monotherapy with either TMP-SMZ or amoxicillin-clavulanate has been associated with a better response rate than doxycycline therapy but has not been studied in prospective comparative trials [18, 19] .
There are no data about the surgical management of mycotic aneurysm secondary to melioidosis. On the basis of experiences with management of mycotic aneurysms due to other infectious agents, aneurysms caused by B. pseudomallei should be debrided and repaired or resected regardless of size, because they have a high risk of rupture [20] . If reconstruction is necessary, either a replacement graft or an extra-anatomical reconstruction is possible. Replacement with an autologous graft is preferred to replacement with homologous or synthetic (dacron/ polytetrafluoroethylene) grafts.
Melioidosis is known to have a high recrudescence rate. Our experience suggests that most patients did not receive appropriate antibiotic therapy before surgery. If the operation involves reconstruction with grafting, it should be assumed that the graft is chronically infected, and antibiotics should be given for a prolonged period or even throughout life, with close surveillance.
In cases of uncomplicated relapse, surgical debridement with drainage of abscess and reinforcement with muscular flap or omentum can be performed, with the administration of a second course of intravenous antibiotic therapy. If there is anastomotic dehiscence, treatment options include a second prosthetic replacement or direct suture reinforcement followed by placement of a muscular flap. Another alternative is extra-anatomical bypass and resection of the prosthesis with suturing of the arterial stumps. However, this procedure still involves the risk of recurrent prosthetic infection and/or aortic stump breakdown. Mycotic aortic aneurysm due to melioidosis remains a difficult disease to manage. Morbidity and mortality are high despite correct diagnosis and aggressive surgical and medical management. We propose that, in areas of endemicity, the diagnosis of melioidosis should always be considered for persons with appropriate risk factors who present with a mycotic aneurysm, so that suitable antibiotic therapy can be initiated as early as possible before surgical intervention. A course of intravenous ceftazidime with a minimum duration of 4-6 weeks should be considered, and maintenance therapy should include a regimen of у2 drugs, to reduce the risk of relapse.
